» Articles » PMID: 1316826

Overrunning and Underrunning in Sequential Clinical Trials

Overview
Publisher Elsevier
Date 1992 Apr 1
PMID 1316826
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

In a sequential (or group sequential) clinical trial the fulfillment of some pre-specified stopping rule will cause recruitment to be terminated. However, for various reasons, data on patients treated according to protocol may continue to accumulate for some time afterward. This phenomenon is called overrunning. On the other hand, a sequential clinical trial might be abandoned before the stopping rule has been fulfilled. This is called underrunning. In both of these situations the procedure for validly analyzing the study is unclear. In this paper we first review the arguments for sequential methodology and the practical way in which it can be integrated with normal clinical trial conduct. Turning next to the special situations of overrunning and underrunning, the conditions under which a valid analysis is possible are identified, and a method of analysis based on the frequentist philosophy is presented. The likelihood of first gaining and then losing significance due to overrunning and its consequences are examined. Examples based on experience with real studies are presented.

Citing Articles

Two-stage group-sequential designs with delayed responses - what is the point of applying corresponding methods?.

Schuurhuis S, Wassmer G, Kieser M, Pahlke F, Kunz C, Herrmann C BMC Med Res Methodol. 2024; 24(1):242.

PMID: 39420280 PMC: 11484224. DOI: 10.1186/s12874-024-02363-7.


Group sequential designs in pragmatic trials: feasibility and assessment of utility using data from a number of recent surgical RCTs.

Parsons N, Stallard N, Parsons H, Haque A, Underwood M, Mason J BMC Med Res Methodol. 2022; 22(1):256.

PMID: 36183085 PMC: 9526271. DOI: 10.1186/s12874-022-01734-2.


Evaluating group-sequential non-inferiority clinical trials following interim stopping: The HIV Prevention Trials Network 083 trial.

Hanscom B, Donnell D, Fleming T, Hughes J, McCauley M, Grinsztejn B Clin Trials. 2022; 19(6):605-612.

PMID: 36053045 PMC: 9691580. DOI: 10.1177/17407745221118371.


Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma....

Hirt C, Hoster E, Unterhalt M, Hanel M, Prange-Krex G, Forstpointner R Hemasphere. 2021; 5(7):e600.

PMID: 34179697 PMC: 8221804. DOI: 10.1097/HS9.0000000000000600.


Evaluation by simulation of clinical trial designs for evaluation of treatment during a viral haemorrhagic fever outbreak.

Manchon P, Belhadi D, Mentre F, Laouenan C BMC Med Res Methodol. 2021; 21(1):98.

PMID: 33952195 PMC: 8099711. DOI: 10.1186/s12874-021-01287-w.